1. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway
    JIE-RU CHEN et al, 2016, International Journal of Oncology CrossRef
  2. Piperlongumine induces apoptosis and G2/M phase arrest in human osteosarcoma cells by regulating ROS/PI3K/Akt pathway
    Jinfeng Zhou et al, 2020, Toxicology in Vitro CrossRef
  3. Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance
    Susana Machado et al, 2020, Cancers CrossRef
  4. Overview of piperlongumine analogues and their therapeutic potential
    Peng Zhu et al, 2021, European Journal of Medicinal Chemistry CrossRef
  5. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells – The involvement of carbonyl reductase 1 inhibition
    Kamil Piska et al, 2019, Chemico-Biological Interactions CrossRef
  6. Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer
    Yin‑Ju Chen et al, 2017, Oncology Letters CrossRef
  7. Piplartine (piperlongumine), oxidative stress, and use in cancer
    Daniel Pereira Bezerra, 2021, Cancer CrossRef
  8. Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc
    Ying-Xia Ning et al, 2017, Oncotarget CrossRef
  9. N-myristoylation of Antimicrobial Peptide CM4 Enhances Its Anticancer Activity by Interacting With Cell Membrane and Targeting Mitochondria in Breast Cancer Cells
    Caiyun Li et al, 2018, Frontiers in Pharmacology CrossRef
  10. A novel platinum complex containing a piplartine derivative exhibits enhanced cytotoxicity, causes oxidative stress and triggers apoptotic cell death by ERK/p38 pathway in human acute promyelocytic leukemia HL-60 cells
    Maiara de S. Oliveira et al, 2019, Redox Biology CrossRef
  11. Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c‑met
    Yan Shu et al, 2017, Oncology Letters CrossRef
  12. Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
    Surya Kant Tripathi et al, 2020, Pharmacological Research CrossRef
  13. Piperlongumine Inhibits Akt Phosphorylation to Reverse Resistance to Cisplatin in Human Non-Small Cell Lung Cancer Cells via ROS Regulation
    Chao Zhang et al, 2019, Frontiers in Pharmacology CrossRef
  14. Piperlongumine (piplartine) as a lead compound for anticancer agents – Synthesis and properties of analogues: A mini-review
    Kamil Piska et al, 2018, European Journal of Medicinal Chemistry CrossRef